Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Astellas Pharma | Contract Pharma
Breaking News, Promotions & Moves

Astellas Pharma

Dr. Peter Carberry has been appointed senior vice president and head of global development operations, Astellas Pharma Global Development (APGD).

Dr. Peter Carberry has been appointed senior vice president and head of global development operations, Astellas Pharma Global Development (APGD). Dr. Carberry is responsible for enhancing the effectiveness and efficiency of the integrated global operational platform including the data sciences and clinical operations organizations.

“We are pleased that Peter has joined Astellas and we know that he will contribute significantly to the development of innovative products,” said Dr. Steven Ryder, president of APGD. Peter is one of several key hires at APGD that were brought on to strengthen and accelerate our research and development function.

Prior to joining the company, Dr. Carberry was the vice president of clinical operations, development planning and performance analysis and the office of international development at Genentech. In that role, he developed a global platform for the execution of non-clinical and clinical activities and established key relationships with company stakeholders. Previously, he was the senior vice president of global clinical operations at Johnson & Johnson Pharmaceutical R&D. Dr. Carberry began his industry career with Pharmacia at the Kalamazoo Research site.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters